Literature DB >> 26060207

Shifts in myocardial fatty acid and glucose metabolism in pulmonary arterial hypertension: a potential mechanism for a maladaptive right ventricular response.

Hiroshi Ohira1, Robert deKemp1, Elena Pena2,3, Ross A Davies1, Duncan J Stewart1,3, George Chandy3,4, Vladimir Contreras-Dominguez3,4, Carole Dennie2,3, Brian Mc Ardle1, Ran Mc Klein1, Jennifer M Renaud1, Jean N DaSilva1, Carolyn Pugliese1, Rosemary Dunne1, Rob Beanlands1,2, Lisa M Mielniczuk1.   

Abstract

AIMS: We investigated the role of metabolic alterations in the development of a maladaptive right ventricular (RV) response in pulmonary arterial hypertension (PAH), which has not previously been undertaken. This study evaluated relationships between glucose and fatty acid metabolism obtained using PET with invasive pulmonary haemodynamics, RV measurements, and RV function to gain insight into the mechanism of RV maladaptation. METHODS AND
RESULTS: Seventeen consecutive PAH patients (mean age 56 ± 15) who underwent right heart catheterization [mean pulmonary arterial pressure (mPAP) 43 ± 12 mmHg] had cardiac 18F-fluoro-2-deoxyglucose (FDG) and (18)F-fluoro-6-thioheptadecanoic acid (FTHA) PET imaging. RV and left ventricular (LV) FDG and FTHA uptake standard uptake values (SUVs) were measured. The SUV was corrected for the partial volume effect (SUVPVE) based on cardiac magnetic resonance imaging (CMR). Right ventricular ejection fraction (RVEF) was determined by CMR. There was a significant positive correlation between mPAP and RV/LV FDG SUVPVE (r = 0.68, P = 0.003), and the ratio of RV/LV FDG SUV : RV/LV FTHA SUV (r = 0.60, P = 0.02). RVEF was negatively correlated with RV/LV FDG SUVPVE uptake (r = -0.56, P = 0.02) and RV/LV FTHA SUVPVE (r = -0.62, P = 0.019).
CONCLUSION: Increased pulmonary arterial pressures are associated with increases in the ratio of FDG/FTHA uptake in the RV. Inverse correlation between the uptake of the metabolic tracers and RV function may reflect a shift towards increased fatty acid oxidation and glycolysis associated with RV failure in maladaptive remodelling. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  cardiac metabolism; maladaptation; positron emission tomography; pulmonary arterial hypertension; right heart failure; right ventricular hypertrophy

Mesh:

Substances:

Year:  2015        PMID: 26060207     DOI: 10.1093/ehjci/jev136

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  20 in total

1.  Positron emission tomography: An additional prognostic tool in dilated cardiomyopathy?

Authors:  Danilo Neglia
Journal:  J Nucl Cardiol       Date:  2015-08-22       Impact factor: 5.952

Review 2.  Emerging therapies for right ventricular dysfunction and failure.

Authors:  Anna Klinke; Torben Schubert; Marion Müller; Ekaterina Legchenko; Jason G E Zelt; Tsukasa Shimauchi; L Christian Napp; Alexander M K Rothman; Sébastien Bonnet; Duncan J Stewart; Georg Hansmann; Volker Rudolph
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

3.  Neuronal nitric oxide synthase modulation of intracellular Ca2+ handling overrides fatty acid potentiation of cardiac inotropy in hypertensive rats.

Authors:  Chun Li Jin; Ming Zhe Yin; Jin Chul Paeng; Seunggyun Ha; Jeong Hoon Lee; Peng Jin; Chun Zi Jin; Zai Hao Zhao; Yue Wang; Keon Wook Kang; Chae Hun Leem; Jong-Wan Park; Sung Joon Kim; Yin Hua Zhang
Journal:  Pflugers Arch       Date:  2017-05-22       Impact factor: 3.657

Review 4.  Positron emission tomography/MRI for cardiac diseases assessment.

Authors:  Osamu Manabe; Noriko Oyama-Manabe; Nagara Tamaki
Journal:  Br J Radiol       Date:  2020-02-14       Impact factor: 3.039

5.  BMPR2 dysfunction impairs insulin signaling and glucose homeostasis in cardiomyocytes.

Authors:  Anna R Hemnes; Joshua P Fessel; Xinping Chen; Shijun Zhu; Niki L Fortune; Christopher Jetter; Michael Freeman; John H Newman; James D West; Megha H Talati
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-12-18       Impact factor: 5.464

6.  Clinical significance of quantitative assessment of right ventricular glucose metabolism in patients with heart failure with reduced ejection fraction.

Authors:  Szu-Ying Tsai; Yen-Wen Wu; Shan-Ying Wang; Yu-Chien Shiau; Kuan-Ming Chiu; Hao-Yuan Tsai; Chien-Lin Lee; Jung-Cheng Hsu; Chung-Ming Tu; Heng-Hsu Lin; Shan-Hui Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-13       Impact factor: 9.236

7.  Assessment of right ventricular metabolism: An emerging tool for monitoring pulmonary artery hypertension.

Authors:  Attila Feher; Albert J Sinusas
Journal:  J Nucl Cardiol       Date:  2016-11-18       Impact factor: 5.952

8.  Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function in a Sugen 5416/hypoxia rat model of severe pulmonary arterial hypertension.

Authors:  Katarzyna Drozd; Ali Ahmadi; Yupu Deng; Baohua Jiang; Julia Petryk; Stephanie Thorn; Duncan Stewart; Rob Beanlands; Robert A deKemp; Jean N DaSilva; Lisa M Mielniczuk
Journal:  J Nucl Cardiol       Date:  2016-09-29       Impact factor: 5.952

9.  Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement.

Authors:  Tim Lahm; Ivor S Douglas; Stephen L Archer; Harm J Bogaard; Naomi C Chesler; Francois Haddad; Anna R Hemnes; Steven M Kawut; Jeffrey A Kline; Todd M Kolb; Stephen C Mathai; Olaf Mercier; Evangelos D Michelakis; Robert Naeije; Rubin M Tuder; Corey E Ventetuolo; Antoine Vieillard-Baron; Norbert F Voelkel; Anton Vonk-Noordegraaf; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2018-08-15       Impact factor: 21.405

10.  The right stuff? Imaging cardiac sympathetic neuronal integrity of the right ventricle in pulmonary arterial hypertension.

Authors:  James T Thackeray
Journal:  J Nucl Cardiol       Date:  2021-01-26       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.